Budesonide Added to Post-Transplantation Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease

被引：0
|
作者：
Vittayawacharin, Pongthep [1 ,2 ]
Jeyakumar, Deepa [1 ]
Lee, Benjamin J. [3 ]
Doh, Jean [3 ]
Griffin, Shawn [4 ]
Van Etten, Richard A. [1 ]
Kongtim, Piyanuch [1 ]
Ciurea, Stefan [1 ]
机构：
[1] Univ Calif Irvine, Dept Med, Div Hematol Oncol, Hematopoiet Stem Cell Transplantat & Cellular The, Orange, CA USA
[2] Mahidol Univ, Siriraj Hosp, Fac Med, Div Hematol,Dept Med, Bangkok, Thailand
[3] Univ Calif Irvine, Dept Pharm, Orange, CA USA
[4] Univ Calif Irvine, Sch Pharm & Pharmaceut Sci, Dept Clin Pharm Practice, Orange, CA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-190530
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil
    Moiseev, Ivan S.
    Pirogova, Olga V.
    Alyanski, Alexandr L.
    Babenko, Elena V.
    Gindina, Tatyana L.
    Darskaya, Elena I.
    Slesarchuk, Olga A.
    Bondarenko, Sergey N.
    Afanasyev, Boris V.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (06) : 1037 - 1042
  • [2] Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding
    Nunes, Natalia S.
    Kanakry, Christopher G.
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [3] Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation
    Mehta, Rohtesh S.
    Saliba, Rima M.
    Rondon, Gabriela
    Al-Atrash, Gheath
    Bashir, Qaiser
    Hosing, Chitra M.
    Kebriaei, Partow
    Khouri, Issa
    Nieto, Yago
    Oran, Betul
    Popat, Uday R.
    Qazilbash, Muzaffar H.
    Ramdial, Jeremy
    Srour, Samer A.
    Champlin, Richard E.
    Rezvani, Katayoun
    Shpall, Elizabeth J.
    Alousi, Amin M.
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (10): : 695.e1 - 695.e10
  • [4] Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus
    B Mookerjee
    V Altomonte
    G Vogelsang
    Bone Marrow Transplantation, 1999, 24 : 517 - 520
  • [5] Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus
    Mookerjee, B
    Altomonte, V
    Vogelsang, G
    BONE MARROW TRANSPLANTATION, 1999, 24 (05) : 517 - 520
  • [6] Post-Transplantation CyclophosphamideBased Graft-versus-Host Disease Prophylaxis
    Bolanos-Meade, J.
    Hamadani, M.
    Wu, J.
    Al Malki, M. M.
    Martens, M. J.
    Runaas, L.
    Elmariah, H.
    Rezvani, A. R.
    Gooptu, M.
    Larkin, K. T.
    Shaffer, B. C.
    El Jurdi, N.
    Loren, A. W.
    Solh, M.
    Hall, A. C.
    Alousi, A. M.
    Jamy, O. H.
    Perales, M. -A.
    Yao, J. M.
    Applegate, K.
    Bhatt, A. S.
    Kean, L. S.
    Efebera, Y. A.
    Reshef, R.
    Clark, W.
    DiFronzo, N. L.
    Leifer, E.
    Horowitz, M. M.
    Jones, R. J.
    Holtan, S. G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (25): : 2338 - 2348
  • [7] Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis
    Hernani, Rafael
    Pinana, Jose Luis
    Perez, Ariadna
    Quintero, Abdiel
    Montoro, Juan
    Hernandez-Boluda, Juan C.
    Carretero, Carlos
    Balaguer-Rosello, Aitana
    Guerreiro, Manuel
    Lorenzo, Ignacio
    Aguilar, Cristobal
    Gimenez, Estela
    Navarro, David
    Sanz, Miguel A.
    Sanz, Jaime
    Solano, Carlos
    EJHAEM, 2021, 2 (02): : 236 - 248
  • [8] Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis
    Salibaaw, Rima M.
    Alousia, Amin M.
    Pidala, Joseph
    Arora, Mukta
    Spellman, Stephen R.
    Hemmer, Michael T.
    Wang, Tao
    Abboudg, Camille
    Ahmed, Sairah
    Antin, Joseph H.
    Beitinjanehi, Amer
    Buchbinder, David K.
    Byrne, Michael
    Cahn, Jean-Yves
    Choen, Hannah
    Hanna, Rabi
    HemattiP, Peiman
    Kamble, Rammurti T.
    Kitkor, Carrie L.
    Laughlin, Mary
    Lekakis, Lazaros
    MacMillan, Margaret L.
    Martino, Rodrigo
    Mehta, Parinda A.
    Nishihori, Taiga
    Patel, Sagar S.
    Perales, Miguel-Angel
    Rangarajan, Hemalatha G.
    Ringden, Olov
    Rosenthal, Joseph
    Savani, Bipin N.
    Schultz, Kirk R.
    Seo, Sachiko
    Teshimaag, Takanori
    van der Poela, Marjolein
    Verdonck, Leo F.
    Weisdorf, Daniel
    Wirk, Baldeep
    Yared, Jean A.
    Schriber, Jeffrey
    Champlin, Richard E.
    Ciurea, Stefan O.
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (10): : 681 - 693
  • [9] Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings
    GB Vogelsang
    S Arai
    Bone Marrow Transplantation, 2001, 27 : 1255 - 1262
  • [10] Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings
    Vogelsang, GB
    Arai, S
    BONE MARROW TRANSPLANTATION, 2001, 27 (12) : 1255 - 1262
12345